loader
Please Wait
Applying Filters...

Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of Drug Master Files (DMF) for 31218 Active Pharmaceutical Ingredient (API) submitted to the U.S. FDA. Original Data : FDA Website

    Client Virtual Booth
    Menu

    ALP Pharm

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 ALP Pharm (1)

    filter

    01 BOSUTINIB (1)

    filter

    01 China (1)

    filter

    01 Active (1)

    filter

    01 Blank (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us

    ALP PHARM BEIJING CO LTD

    Contact Supplier
      Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
      Post an Enquiry Post an Enquiry
      Flag China
      Virtual Booth Virtual Booth
      Digital Content Digital Content

      BOSUTINIB

      PDF Supplier PDF
      URL Supplier Web Content
      31218
      Active
      2016-12-12
      N/A
      II
      ASK
      US
      PHARMACOMPASS
      Upload
      your Marketing & Sales content

      Looking for Drug Master Files (DMF) for 31218 of Alp Pharm Beijing Co Ltd

      Looking for Drug Master Files (DMF) for 31218 of Alp Pharm Beijing Co Ltd 1

      20

      Alp Pharm Beijing Co Ltd, based in China, is a pharmaceutical company.

      One of their notable products is BOSUTINIB, with a corresponding US DMF Number 31218.

      Remarkably, this DMF maintains an Active status since its submission on December 12, 2016, highlighting commitment to regulatory compliance.

      Post Enquiry
      POST ENQUIRY